NanoViricides (NNVC)
XASE:NNVC
Want to see NNVC full AI Analyst Report?
NNVC Stock Chart & Stats
$1.13
-$0.10(-6.54%)
At close: 4:00 PM EST
$1.13
-$0.10(-6.54%)
Day’s Range― - ―
52-Week Range$0.85 - $2.23
Previous CloseN/A
Volume409.80K
Average Volume (3M)143.34K
Market Cap
$32.18M
Enterprise Value$20.73M
Total Cash (Recent Filing)$3.21M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.02
Next Earnings
Nov 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.43
Shares Outstanding22,982,817
10 Day Avg. Volume199,739
30 Day Avg. Volume143,335
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)2.82
Price to Sales (P/S)0.00
P/FCF Ratio-2.48
Enterprise Value/Market Cap0.64
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-159.92
Enterprise Value/Ebitda-2.75
Forecast
1Y Price Target
$6.00Price Target Upside430.97% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.35
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary PlatformA platform approach that mimics host-cell binding to neutralize viruses offers durable competitive advantage: it can be applied across multiple viral targets, supports pipeline expansion and reuse of core R&D, and creates long-term optionality beyond a single drug candidate.
Low LeverageNear-zero debt materially lowers bankruptcy and interest-rate risk, preserving strategic flexibility for a pre-commercial biotech. Low leverage makes future financing decisions less constrained by covenants and maintains optionality to pursue R&D, partnerships, or acquisitions.
Clinical Program OptionalityManagement’s NV-387 strategy — pursuing NV-387 alone and a remdesivir-encapsulated form, plus readiness to use an existing Mpox trial site in DRC — increases program optionality. Multiple development paths and practical trial access improve chances of a durable clinical or strategic outcome.
Bears Say
No RevenueA sustained pre-commercial profile with zero revenue means the company lacks operating cash generation and is reliant on external funding. Without revenue, the firm cannot demonstrate commercial viability, limiting long-term self-sufficiency and increasing investor risk.
Persistent Cash BurnConsistent annual losses and negative operating/free cash flow (historical FCF burn roughly $6–9M) create a durable financing need. Persistent burn reduces runway, forces frequent capital raises, and constrains sustained investment in clinical development and commercialization.
Dependence On Equity FinancingRecent registered direct offering underscores reliance on capital markets to fund operations. Recurrent financings, combined with a materially declined equity base, imply dilution risk and weaken the company’s capital cushion, affecting long-term strategic flexibility.
NanoViricides News
NNVC FAQ
What was NanoViricides’s price range in the past 12 months?
NanoViricides lowest stock price was $0.85 and its highest was $2.23 in the past 12 months.
What is NanoViricides’s market cap?
NanoViricides’s market cap is $32.18M.
When is NanoViricides’s upcoming earnings report date?
NanoViricides’s upcoming earnings report date is Nov 23, 2026 which is in 155 days.
How were NanoViricides’s earnings last quarter?
NanoViricides released its earnings results on Nov 24, 2025. The company reported -$0.135 earnings per share for the quarter, beating the consensus estimate of -$0.18 by $0.045.
Is NanoViricides overvalued?
According to Wall Street analysts NanoViricides’s price is currently Undervalued.
Does NanoViricides pay dividends?
NanoViricides does not currently pay dividends.
What is NanoViricides’s EPS estimate?
NanoViricides’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does NanoViricides have?
NanoViricides has 22,982,817 shares outstanding.
What happened to NanoViricides’s price movement after its last earnings report?
NanoViricides reported an EPS of -$0.135 in its last earnings report, beating expectations of -$0.18. Following the earnings report the stock price went down -2.362%.
Which hedge fund is a major shareholder of NanoViricides?
Currently, no hedge funds are holding shares in NNVC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NanoViricides Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (430.97% Upside)
$6.00 (430.97% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.2%
Last 30 Days ▲ 5.7%
Last 30 Days ▲ 5.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
0.67%
12-Months-Change
Fundamentals
Return on Equity
-92.69%
Trailing 12-Months
Asset Growth
1.86%
Trailing 12-Months
Company Description
NanoViricides
NanoViricides, Inc. operates as a nano-biopharmaceutical entity, specializing in the research, development, and market introduction of pharmaceutical solutions to combat viral infections. The company's robust product pipeline includes a Human Coronavirus Program, specifically engineered to tackle both COVID-19 and various seasonal coronaviruses. For herpes-related conditions, it offers HerpeCide in multiple forms: dermal topical and eye drops to treat ailments such as shingles, postherpetic neuralgia (PHN), chickenpox, recurrent herpes labialis, genital herpes, and ocular herpes keratitis. An intraocular injectable version of HerpeCide is also under development for viral acute retinal necrosis. Another significant therapeutic candidate is FluCide, a broad-spectrum anti-influenza nanoviricide, designed for both hospitalized patients via injection and outpatients through an oral formulation. NanoViricides also develops specialized nanoviricide eye drops for viral diseases affecting the external eye, DengueCide for various strains of Dengue viruses, and HIVCide, an anti-HIV nanoviricide specifically engineered to resist viral escape. Furthermore, the company is actively advancing additional nanoviricide drug projects targeting a diverse range of viruses and indications, alongside expanding its HerpeCide program to encompass a broader spectrum of herpes viruses and associated conditions. NanoViricides, Inc. was established in 2005 and maintains its corporate headquarters in Shelton, Connecticut.
NNVC Stock 12 Month Forecast
Average Price Target
$6.00
▲(430.97% Upside)
Technical Analysis
Ownership Overview
―
Insiders
2.99% Mutual Funds
0.92% Other Institutional Investors
92.37% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---